ResultsIQ › Latest results › Hester Biosciences Limited
Hester Biosciences Limited Q2 FY27 earnings call summary
NSE: HESTERBIO · BSE: 524669
Earnings call of 5 Nov 2026, summarised by AI from the filing.
Consolidated PAT rose 44% in Q2 and 71% in H1, the H1 figure including a Q1 exceptional gain from the Gates Foundation loan amendment.
Key takeaways
- Consolidated PAT Consolidated PAT rose 44% in Q2 and 71% in H1, the H1 figure including a Q1 exceptional gain from the Gates Foundation loan amendment.
- Poultry driver Poultry Healthcare revenue grew 37% in H1 on institutional business, deeper penetration and the H9N2 vaccine.
- Nepal risk Nepal PPR eradication procurement did not materialise at the scale originally envisaged.
Hester Biosciences Limited Q2 FY27 results
As filed: Revenue ₹97.9 cr (+38% year on year), EBITDA ₹32.7 cr (+197% year on year), PAT ₹20.6 cr (+47% year on year), EBITDA margin 33.4% (+1,000 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹77.2 cr (−8% year on year), EBITDA ₹22.8 cr (−1% year on year), PAT ₹96.7 cr (−25% year on year), EBITDA margin 29.5% (+211 bps). Score 30 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin rose 211 bps year on year. Tax rate 5%. Revenue fell 23% from last quarter. Share price after the results: −7.8% in 29 days (Nifty 500: +0.8%).
- Q4 FY26: Revenue ₹100 cr (+22% year on year), EBITDA ₹34.3 cr (+81% year on year), PAT ₹16.6 cr (+300% year on year), EBITDA margin 34.3% (+1,000 bps). Score 87 of 100, Above trend. Revenue and profit before exceptional items growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 1000 bps year on year. Tax rate 37%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +12.2% in 28 days (Nifty 500: −0.1%).
- Q3 FY26: Revenue ₹77.4 cr (+23% year on year), EBITDA ₹17.8 cr (+300% year on year), PAT ₹9.3 cr (−15% year on year), EBITDA margin 23.0% (+1,000 bps). Score 71 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin rose 1000 bps year on year. Consolidated profit -15% but standalone +167%. Profit fell 34% from last quarter. Share price after the results: +6.5% in 28 days (Nifty 500: +0.1%).
- Q2 FY26: Revenue ₹71.0 cr (−15% year on year), EBITDA ₹11.0 cr (−42% year on year), PAT ₹14.0 cr (+75% year on year), EBITDA margin 15.5% (−713 bps). Score 21 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was above it. EBITDA margin fell 713 bps year on year. Other income 67% of PBT. Consolidated profit +75% but standalone -22%. Revenue fell 15% from last quarter. Profit rose ₹6.0 cr on a year ago, more than the ₹4.0 cr it added the year before. Share price after the results: −2.1% in 30 days (Nifty 500: +0.2%).
- Q1 FY26: Revenue ₹84.0 cr (+2% year on year), EBITDA ₹23.0 cr (+28% year on year), PAT ₹17.0 cr (+143% year on year), EBITDA margin 27.4% (+543 bps). Score 62 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well above it. EBITDA margin rose 543 bps year on year. Consolidated profit +143% but standalone +0%. Share price after the results: +3.9% in 28 days (Nifty 500: −2.0%).
- Q4 FY25: Revenue ₹82.0 cr (+4% year on year), EBITDA ₹19.0 cr (+19% year on year), PAT ₹2.0 cr (−67% year on year), EBITDA margin 23.2% (+292 bps). Score 39 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well below it. EBITDA margin rose 292 bps year on year. Tax rate 100%. Consolidated profit -67% but standalone +43%. Profit fell 82% from last quarter. Share price after the results: +10.0% in 28 days (Nifty 500: +6.1%).
- Q3 FY25: Revenue ₹63.0 cr (−6% year on year), EBITDA ₹4.0 cr (−60% year on year), PAT ₹11.0 cr (+175% year on year), EBITDA margin 6.4% (−858 bps). Score 29 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was well above it. EBITDA margin fell 858 bps year on year. Other income 67% of PBT. Consolidated profit +175% but standalone -33%. Revenue fell 25% from last quarter.
Past price moves after results do not indicate future moves. Not a recommendation.
Hester Biosciences Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (5 Nov 2026)
- Q1 FY27: Earnings call (30 Jul 2026), Results press release (30 Jul 2026)
- Q4 FY26: Earnings call (15 May 2026)
- Q3 FY26: Earnings call (30 Jan 2026)
- Q2 FY26: Earnings call (12 Nov 2025), Results press release (12 Nov 2025)
- Q1 FY26: Earnings call (1 Aug 2025)
- Q4 FY25: Earnings call (9 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.